USA, France, Germany, Italy, Spain, UK, Brazil and Japan Autoimmune Haemolytic Anemia Market Forecast 2016-2026 - Research and Markets

DUBLIN, August 10, 2016 /PRNewswire/ --

Research and Markets has announced the addition of the "Autoimmune Haemolytic Anemia Forecast in 8 Major Markets 2016-2026" report to their offering.

Autoimmune haemolytic anaemia (AIHA) is an immune disorder caused by auto-antibodies against unmodified autologous red blood cells and can range in presentation from a mild illness to a rapidly fatal severe condition.

This report provides the current incident population for AIHA across 8 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil and Japan) split by gender and 5-year age cohort. Along with the current incidence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team, several of the main symptoms and co-morbidities of AIHA's have been quantified and presented alongside the overall incidence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for AIHA include:

- Lymphoproliferative conditions:

- - CLL

- - HL

- - NHL

- Myeloproliferative conditions:

- - Multiple myeloma

- - Myelofibrosis

- - MGUS

- Autoimmune conditions:

- - RA

- - SLE

- - Polyarteritis nodosa

- Infections:

- - Pneumonia & Tuberculosis

- - Syphilis

- - Epstein-Barr

- - Chronic active hepatitis

- - Mononucleosis

Reasons to Buy:

- Able to quantify patient populations in global AIHA's market to target the development of future products, pricing strategies and launch plans.

- Gain further insight into the incidence of the subdivided types of AIHA and identify patient segments with high potential.

- Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.

- Provide a level of understanding on the impact from specific co-morbid conditions on AIHA's incident population.

- Identify sub-populations within AIHA which require treatment.

- Gain an understanding of the specific markets that have the largest number of AIHA patients.

Key Topics Covered:

1. List of Tables and Figures

2. Introduction

3. Cause of the Disease

4. Risk Factors & Prevention

5. Diagnosis of the Disease

6. Variation by Geography/Ethnicity

7. Disease Prognosis & Clinical Course

8. Clinical Management of AIHA - Transfusion therapy in AIHA

9. Key Co-morbid Conditions/Features Associated with the Disease

10. Methodology for Quantification of Patient Numbers

11. Top-Line Incidence for AIHA

12 Subtypes of AIHA patients

- Warm AIHA patients

- Cold AIHA patients

- Mixed-type AIHA patients

13. Market Forecast for AIHA

- 1st Line Treatment Options within Warm & Mixed-type AIHA

- 2nd Line Treatment Options within Warm & Mixed-type AIHA

- 1st Line Treatment Options within Cold AIHA

- 2nd Line Treatment Options within Cold AIHA

- Requirement for Blood Transfusions within AIHA

14. Methodology for Forecast Figures

15. Abbreviations used in the report

16. Patient-Based Offering

17. Online Pricing Data and Platforms

18. References

19. Appendix

For more information visit http://www.researchandmarkets.com/research/c755wk/autoimmune

Media Contact:

Laura Wood, Senior Manager

[email protected] 

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Related Links

http://www.researchandmarkets.com